Robert Groves, MD, leads a panel discussion surrounding risk factors related to heart disease.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD, executive vice president and chief medical officer, Banner |Aetna; Eugene E. Wright Jr, MD, consulting associate, Department of Medicine, Duke University Medical Center, and medical director for performance improvement, South Piedmont Area Health Education Center; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN, associate chief nursing officer, research and innovation, and clinical nurse specialist at the Kaufman Center for Heart Failure Treatment and Recovery at the Cleveland Clinic; Nihar Desai, MD, MPH, vice chief, cardiovascular medicine at the Yale School of Medicine; and Kelly Marie Axsom, MD, medical director, Centralized Heart Failure Management Program at New York Presbyterian Hospital, and assistant professor of medicine at Columbia University Medical Center. The panel discusses updates in heart failure management, analyzing unmet needs and future considerations. Desai provides an overview of heart failure epidemiology, noting the significant burden in the US with an estimated 7 to 8 million individuals affected. Prevalence is increasing due to aging population and rise in risk factors like hypertension, kidney disease, diabetes, and valvular heart disease. There are also disparities across sex, race, and ethnicity. Albert expands on risk factors, highlighting lifestyle choices like sedentary behaviors and comorbid conditions like obesity and genetics. The panel aims to highlight key guideline updates and the evolving disease landscape regarding heart failure.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Gene Therapy Enhances Visual Processing for Inherited Retinal Disease
December 3rd 2024Gene therapy partially restores visual processing in the geniculostriate pathway of patients with Leber congenital amaurosis type 2 while maintaining compensatory activity in the retinotectal pathway.
Read More
New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia
December 2nd 2024Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are: −11/+11 for symptom burden, −16/+16 for physical condition/fatigue, and −16/+13 for worries/fears.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS
November 29th 2024The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.
Read More